Analysts Anticipate Arbutus Biopharma Co. (NASDAQ:ABUS) to Post -$0.13 Earnings Per Share

Equities research analysts expect Arbutus Biopharma Co. (NASDAQ:ABUSGet Rating) to post earnings per share of ($0.13) for the current quarter, according to Zacks. Two analysts have made estimates for Arbutus Biopharma’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.10). Arbutus Biopharma reported earnings per share of ($0.23) in the same quarter last year, which indicates a positive year over year growth rate of 43.5%. The company is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Arbutus Biopharma will report full year earnings of ($0.51) per share for the current fiscal year, with EPS estimates ranging from ($0.60) to ($0.39). For the next financial year, analysts anticipate that the business will report earnings of ($0.58) per share, with EPS estimates ranging from ($0.80) to ($0.40). Zacks’ EPS averages are an average based on a survey of research analysts that cover Arbutus Biopharma.

Arbutus Biopharma (NASDAQ:ABUSGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $12.58 million for the quarter, compared to analyst estimates of $5.77 million. Arbutus Biopharma had a negative net margin of 352.49% and a negative return on equity of 121.30%. During the same quarter last year, the firm earned ($0.21) EPS.

ABUS has been the subject of several research reports. Chardan Capital boosted their price objective on shares of Arbutus Biopharma from $5.50 to $6.00 and gave the company a “buy” rating in a report on Friday, March 4th. HC Wainwright boosted their target price on shares of Arbutus Biopharma from $8.00 to $8.50 and gave the stock a “buy” rating in a report on Monday, March 14th. StockNews.com assumed coverage on shares of Arbutus Biopharma in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Jefferies Financial Group raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating and upped their price target for the company from $4.00 to $5.00 in a research note on Wednesday, February 2nd. Finally, Zacks Investment Research downgraded shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Arbutus Biopharma currently has an average rating of “Buy” and an average target price of $6.25.

A number of institutional investors have recently modified their holdings of ABUS. Front Row Advisors LLC bought a new stake in shares of Arbutus Biopharma in the 1st quarter valued at about $31,000. QCM Cayman Ltd. bought a new stake in shares of Arbutus Biopharma in the 4th quarter valued at about $40,000. Traynor Capital Management Inc. bought a new stake in shares of Arbutus Biopharma in the 4th quarter valued at about $42,000. Credit Suisse AG bought a new stake in shares of Arbutus Biopharma in the 4th quarter valued at about $44,000. Finally, Parametric Portfolio Associates LLC bought a new stake in shares of Arbutus Biopharma in the 4th quarter valued at about $53,000. Institutional investors own 26.66% of the company’s stock.

NASDAQ ABUS traded up $0.17 during trading hours on Friday, reaching $2.48. 1,075,260 shares of the company’s stock traded hands, compared to its average volume of 2,081,802. The firm has a market cap of $368.85 million, a PE ratio of -3.40 and a beta of 2.66. Arbutus Biopharma has a 52-week low of $1.93 and a 52-week high of $6.50. The firm has a 50-day simple moving average of $2.60 and a 200 day simple moving average of $3.10.

Arbutus Biopharma Company Profile (Get Rating)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.

Further Reading

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.